Adjuvant Treatment in a Young Woman with Early Breast Cancer and a Pathogenic BRCA1 Variant
A 34-year-old premenopausal woman undergoes breast-conserving surgery and sentinel node biopsy for a 2.2 cm grade 3 invasive ductal carcinoma. Pathology: ER 5%, PR 0%, HER2-negative (triple-negative), one micrometastasis in the sentinel node (0.3 mm), margins clear. Germline testing shows a pathogenic BRCA1 variant. She has no children yet and wants to preserve fertility. She asks whether she needs chemotherapy, radiation, and whether she should have her ovaries removed now.
1. Construct an adjuvant plan covering chemotherapy, locoregional therapy, and genetic-risk surgery, with the reasoning behind each component.
Read the worked answer
Chemotherapy: The tumor is triple-negative, grade 3, node-positive (micrometastasis), and she is young - all adverse features. Adjuvant anthracycline–taxane chemotherapy is indicated; for BRCA1-associated triple-negative disease, platinum-containing regimens and dose-dense schedules are reasonable options, and the choice should be discussed at a multidisciplinary tumor board. Neoadjuvant chemotherapy could have been considered, but she has already had surgery.
Locoregional therapy: Breast-conserving surgery plus whole-breast radiation is appropriate and gives survival equivalent to mastectomy. A micrometastasis (pN1mi) generally does not mandate axillary dissection or regional nodal irradiation, but the radiation oncologist should decide based on the full nodal picture. Because she carries BRCA1, contralateral risk-reducing mastectomy should be offered and discussed; it reduces contralateral risk but does not improve survival.
Genetic-risk surgery: Risk-reducing salpingo-oophorectomy is recommended for BRCA1 carriers, typically at age 35–40 or after completion of childbearing. Because she wants children, the timing should be deferred until after family completion, with counseling that this delays but does not eliminate the benefit. Fertility preservation (oocyte or embryo cryopreservation) must be offered before chemotherapy starts.
2. She asks whether she should have a PARP inhibitor after chemotherapy. What is the evidence, and which patients benefit?
Read the worked answer
Adjuvant olaparib (a PARP inhibitor) improves invasive disease-free survival in patients with high-risk, HER2-negative early breast cancer carrying a germline BRCA1/2 mutation who have completed local therapy and neoadjuvant or adjuvant chemotherapy. The benefit is greatest in patients with node-positive or high-risk node-negative disease, which includes her (grade 3, T2, pN1mi, triple-negative).
The decision should be individualized: the absolute benefit is modest, and the main toxicities are fatigue, nausea, and anemia. She should be counseled that the drug is taken for one year and requires monitoring of blood counts. Because she is young and triple-negative with a BRCA1 mutation, she falls into the population in which the trial evidence supports offering it. The discussion should include cost, access, and her fertility plans, since the drug is not compatible with pregnancy and contraception is required during treatment.